Current therapy of cutaneous melanoma

Plastic and Reconstructive Surgery

Volumn 105, Issue 5, 2000, Pages 1774-1799

  Wagner, Jeffrey D ^a   Gordon, Michael S ^a   Chuang, Tsu Yi ^a   Coleman III, John J ^a  

^a RT 471 Cancer Pavilion Bldg ^*

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RESEARCH; CANCER STAGING; HUMAN; LYMPH NODE METASTASIS; MELANOMA; PRIORITY JOURNAL; REVIEW;

EID: 0034109653     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006534-200004050-00028     Document Type: Review

References (159)

1. Glocker-Reis, L. A., Miller, B. A., Hankey, B. F., et al. (Eds.). SEER Cancer Statistics Review, 1973-1991. Bethesda, Md.: National Cancer Institute, 1994. National Institutes of Health publication no. 94: 2789. (Tables and graphs.)
2. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin. 49: 8, 1999.
3. Rigel, D. S., Friedman, R. J., and Kopf, A. W. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century. J. Am. Acad. Dermatol. 34: 839, 1996.
4. SEER Cancer Statistics Review, 1973-1995. Bethesda, Md.: National Cancer Institute, 1998. National Institute of Health Publication No. 98-2789.
5. Johnson, T. M., Smith, J. W., II, Nelson, B. R., and Chang, A. Current therapy for cutaneous melanoma. J. Am. Acad. Dermatol. 32: 689, 1995.
6. Friedman, J. F., Heilman E. R., Gottlieb, G. J., Waldo, E. D., and Rigel, D. S. Malignant Melanoma: Clinicopathologic Correlations. In R. J. Friedman, D. S. Rigel, A. W. Kopf, M. N. Harris, and D. Baker (Eds.), Cancer of The Skin. Philadelphia: Saunders, 1991. Pp. 148-176.
7. Clark, W. H., Jr., Mastrangelo, M. J., Ainsworth, A. M., et al. Current concepts of the biology of human cutaneous malignant melanoma. Adv. Cancer Res. 24: 267, 1977.
8. Lederman, J. S., and Sober, A. J. Does biopsy type influence survival in clinical stage I cutaneous melanoma? J. Am. Acad. Dermatol. 13: 983, 1985.
9. Epstein, E., Bragg, K., and Linden, G. Biopsy and prognosis of malignant melanoma. J.A.M.A. 208: 1369, 1969.
10. National Institutes of Health Consensus Conference. Diagnosis and treatment of early melanoma. J.A.M.A. 268: 1314, 1992.
11. Balch, C. M., Soong, S. J., Shaw, H. M., et al. An Analysis of Prognostic Factors in 8,500 Patients with Cutaneous Melanoma. In C. M. Balch, A. N. Houghton, G. W. Milton, et al. (Eds.), Cutaneous Melanoma, 2nd Ed. Philadelphia: Lippincott, 1992. Pp. 165-187.
12. Soong, S. J., and Weiss, H. L. Predicting Outcome in Patients with Localized Melanoma. In C. M. Balch, A. N. Houghton, A. J. Sober, and S. J. Soong (Eds.), Cutaneous Melanoma, 3rd Ed. St. Louis: Quality Medical Publishing, 1998. Pp. 11-35.
13. Breslow, A. Thickness, cross-sectional areas, and depth of invasion in the prognosis of cutaneous melanoma. Ann. Surg. 172: 902, 1970.
14. Balch, C. M., Murad, T. M., Soong, S. J., Ingalls, A. L., Halpern, N. B., and Maddox, W. A. A multifactorial analysis of melanoma: Prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann. Surg. 188: 732, 1978.
15. Van der Esch, E. P., Cascinelli, N., Preda, F., Morabito, A., and Bufalino, R. Stage I melanoma of the skin. Evaluation of prognosis according to histologic characteristics. Cancer 48: 1668, 1981.
16. Pontikes, L. A., Temple, W. J., Cassar, S. L., et al. Influence of level and depth on recurrence rate in thin melanomas. Am. J. Surg. 165: 225, 1993.
17. Mansson-Brahme, E., Carstensen, J., Erhardt, K., Lagerlof, B., Ringborg, U., and Rutqvist, L. E. Prognostic factors in thin cutaneous malignant melanoma. Cancer 73: 2324, 1994.
18. Thorn, M., Ponten, F., Bergstrom, R., Sparen, S. P., and Adami, H. O. Clinical and histopathologic predictors of survival in patients with malignant melanoma: A population-based study in Sweden. J. Natl. Cancer Inst. 86: 761, 1994.
19. Schmoecke, C., Bockelbrink, A., Bockelbrink, H., Koutsis, J., and Braun-Falco, O. Low- and high-risk malignant melanoma: I. Evaluation of clinical and histopathological prognosticators in 585 cases. Eur. J. Cancer Clin. Oncol. 19: 227, 1983.
20. Paladugu, R. R., and Yonemoto, R. H. Biologic behavior of thin malignant melanomas with regressive changes. Arch. Surg. 118: 41, 1983.
21. McGovern, V. J., Shaw, H. M., and Milton, G. W. Prognosis in patients with thin malignant melanoma: Influence of regression. Histopathology 7: 673, 1983.
22. Kelly, J. W., Sagebiel, R. W., Calderon, W., Murillo, L., Dakin, R. L., and Blois, M. S. The frequency of local recurrence and microsatellitosis as a guide to reexcision margin for cutaneous malignant melanoma. Ann. Surg. 200: 759, 1984.
23. Harrist, T. J., Rigel, D. S., Day, C. L., Jr., et al. "Microscopic satellites" are more highly associated with lymph node metastases than is primary melanoma thickness. Cancer 53: 2183, 1984.
24. Carlson J. A., Dickersin, G. R., Sober, A. J., and Barnhill, R. L. Desmoplastic neurotropic melanoma: A clinicopathologic analysis of 28 cases. Cancer 75: 478, 1995.
25. Quinn, M. J., Crotty, K. A., Thompson J. F., Coates, A. S., O'Brien, C. J., and McCarthy, W. H. Desmoplastic and desmoplastic neurotropic melanoma: Experience with 280 patients. Cancer 83: 1128, 1998.
26. Hacene, K., Le Doussal, V., Brunet, M., Lemoine, F., Guerin, P., and Hebert, H. Prognostic index for clinical stage I cutaneous malignant melanoma. Cancer 43: 2991, 1983.
27. Day, C. L., Jr., Sober, A. J., Kopf, A. W., et al. A prognostic model for clinical stage I melanoma of the trunk: Location near the midline is not an independent risk factor for recurrent disease. Am. J. Surg. 142: 247, 1981.
28. Kopf, A. W., Gross, D. F., Rogers, G. S., et al. Prognostic index for malignant melanoma. Cancer 59: 1236, 1987.
29. Hsueh, E. C., Lucci, A., Qi, K., and Morton, D. L. Survival of patients with melanoma of the lower extremity decreases with distance from the trunk. Cancer 85: 383, 1999.
30. DeMatos, P., Tyler, D. S., and Seigler, H. F. Malignant melanoma of the mucous membranes: A review of 119 cases. Ann. Surg. Oncol. 5: 733, 1998.
31. Stidham, K. R., Johnson, J. L., and Seigler, H. F. Survival superiority of females with melanoma: A multi-variate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch. Surg. 129: 316, 1994.
32. Schuchter, L., Schultz, D. J., Synnestvedt, M., et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. Ann. Intern. Med. 125: 369, 1996.
33. Fleming, I. D., Cooper, J. S., Henson, D. E., et al. (Eds.). AJCC Cancer Staging Manual, 5th Ed. Philadelphia: Lippincott-Raven, 1997. Pp. 163-170.
34. Khansur, T., Sanders, J., and Das, S. K. Evaluation of staging workup in malignant melanoma. Arch. Surg. 124: 847, 1989.
35. Kuvshinoff, B. W., Kurtz, C., and Coit, D. G. Computed tomography in evaluation of patients with stage III melanoma. Ann. Surg. Oncol. 4: 252, 1997.
36. Ardizzoni, A., Grimaldi, A., Repetto, L., Bruzzone, M., Sertoli, M. R., and Rosso, R. Stage I-II melanoma: The value of metastatic work-up. Oncology 44: 87, 1987.
37. Weiss, M., Loprinzi, C. L., Creagan, E. T., Dalton, R. J., Novotny, P., and O'Fallon, J. R. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. J.A.M.A. 274: 1703, 1995.
38. Buzaid, A. C., Sandler, A. B., Mani, S., et al. Role of computed tomography in the staging of primary melanoma. J. Clin. Oncol. 11: 638, 1993.
39. Coit, D., Ghossein, R., Vlamis, V., et al. Prognostic significance of tyrosinase mRNA in the peripheral blood and/or bone marrow of melanoma patients rendered surgically free of disease (Abstract). Proc. Am. Soc. Clin. Oncol. 17: 514, 1998.
40. Palmieri, G., Strazzullo, M., Ascierto, P. A., Satriano, S. M., Daponte, A., and Castello, G. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. J. Clin. Oncol. 17: 304, 1999.
41. Boni, R., Huch-Boni, R., Steinert, H., Drummer, R., Burg, G., and von Schulthess, G. K. Anti-melanoma monoclonal antibody 225.28S immunoscintigraphy in metastatic melanoma. Dermatology 191: 119, 1995.
42. Divgi, C. R., and Larson, S. M. Radiolabeled monoclonal antibodies in the diagnosis and treatment of malignant melanoma. Semin. Nucl. Med. 19: 252, 1989.
43. Kagan, R., Witt, T., Bines, S., Mesleh, G., and Economou, S. Gallium-67 scanning for malignant melanoma. Cancer 61: 272, 1988.
44. Gritters, L. S., Francis, I. R., Zasadny, K. R., and Wahl, R. L. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J. Nucl. Med. 34:1420, 1993.
45. Boni, R., Boni, R. A., Steinert, H., et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxyD-glucose. Br. J. Dermatol. 132: 556, 1995.
46. Wagner, J. D., Schauwecker, D., Hutchins, G., and Coleman, J. J., III. Initial assessment of positron emission tomography for detection of nonpalatable regional lymphatic metastases in melanoma. J. Surg. Oncol. 64: 181, 1997.
47. Steinert, H. C., Huch Boni, R. A., Buck, A., et al. Malignant melanoma: Staging with whole-body positron emission tomography and 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 195: 705, 1995.
48. Rinne, D., Baum, R. P., Hor, G., and Kaufmann, R. Primary staging and follow-up of high risk melanoma patients with whole-body 18 F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients. Cancer 82: 1664, 1998.
49. Kirgan, D., Guenther, J., Bhattathiry, M., et al. The importance of whole body PET scans on the management of metastatic malignant melanoma (Abstract). Proc. Am. Soc. Clin. Oncol. 13: 396, 1994.
50. Blessing, C., Feine, U., Geiger, L., Carl, M., Rassner, G., and Fierlbeck, G. Positron emission tomography and ultrasonography: A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch. Dermatol. 131: 1394, 1995.
51. Damian, D. L., Fulham, M. J., Thompson, E., and Thompson, J. F. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res. 6: 325, 1996.
52. Macfarlane, D. J., Sondak, V., Johnson, T., and Wahl, R. L. Prospective evaluation of 2-(18F)-2-deoxyglucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J. Clin. Oncol. 16: 1770, 1998.
53. Yao, W. J., Hoh, C. K., Glaspy, F., et al. Whole body FDG-PET imaging for staging of malignant melanoma: Is it cost effective? (Abstract) J. Nucl. Med. 35: 8, 1994.
54. Wagner, J. D., Schauwecker, D. S, Davidson, D., et al. Prospective study of FDG-PET imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J. Clin. Oncol. 17: 1508, 1999.
55. Handley, W. S. The pathology of melanotic growths in relation to their operative treatment. Lancet 1:927, 1907.
56. Breslow, A., and Macht, S. D. Optimal size of resection margin for thin cutaneous melanoma. Surg. Gynecol. Obstet. 145: 691, 1997.
57. Balch, C. M., Murad, T. M., Soong, S. J., Ingalls, A. L., Richards, P. C., and Maddox, W. A. Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer 43: 883, 1979.
58. Elder, D. E., Guerry, D., IV, Heiberger, R. M., et al. Optimal resection margin for cutaneous malignant melanoma. Plast. Reconstr. Surg. 71: 66, 1983.
59. Goldman, L. I., and Byrd, R. Narrowing resection margins for patients with low-risk melanoma Am. J. Surg. 155: 242, 1988.
60. Day, C. L., Jr., Mihm, M. C., Jr., Sober, A. J., Fitzpatrick, T. B., and Malt, R. A. Narrower margins for clinical stage I malignant melanoma. N. Engl. J. Med 306: 479, 1982.
61. O'Rourke, M. G., and Altmann, C. R. Melanoma recurrence after excision: Is a wide margin justified? Ann. Surg. 217: 2, 1993.
62. Milton, G. W., Shaw, H. M, and McCarthy, W. H. Resection margins of melanoma. Aust. N.Z. J. Surg. 55: 225, 1985.
63. Balch, C. M., Urist, M. M., Karakousis, C. P., et al. Efficacy of 2-cm surgical margins for intermediate thickness melanomas (1 to 4 mm). Ann. Surg. 218: 262, 1993.
64. Ringborg, U., Andersson, R., Eldh, J., et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: Randomized study by the Swedish Melanoma Study Group. Cancer 77: 1809, 1996.
65. Veronesi, U., Cascinelli, N., Adamus, J., et al. Thin stage I primary cutaneous malignant melanoma: Comparison of excision with margins of 1 or 3 cm N. Engl. J. Med. 318: 1159, 1988.
66. Ross, M. I., and Balch, C. M. Surgical Treatment of Primary Melanoma. In C. M. Balch, A. N. Houghton, A. J. Sober, and S. J. Soong (Eds.), Cutaneous Melanoma, 3rd Ed. St. Louis: Quality Medical Publishing 1998. Pp. 141-153.
67. Heaton, K. M., Sussman, J. J., and Gershenwald, J. E., et al. Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann. Surg. Oncol. 5: 322, 1998.
68. Coit, D., Wallack, M., and Balch, C. Society of surgical oncology practice guidelines: Melanoma surgical practice guidelines. Oncology 11: 1317, 1997.
69. Cooper, P. H., Mills, S. E., and Allens, M. S., Jr. Malignant melanoma of the anus: Report of 12 patients and analysis of 255 additional cases. Dis. Colon Rectum 25: 693, 1982.
70. Siegal, B., Cohen, D., and Jacob, E. T. Surgical treatment of anorectal melanomas. Am. J. Surg. 146: 336, 1983.
71. Brady, M. S., Kavolius, J. P., and Quan, S. H. Anorectal melanoma: A 64 year experience at Memorial Sloan-Kettering Cancer Center. Dis. Colon Rectum 38:146, 1995.
72. Cohen, M. H., Ketcham, A. S., Felix, E. L., et al. Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma. Ann. Surg. 186: 635, 1977.
73. Callery, C., Cochran, A. J., Roe, D. J., et al. Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. Ann. Surg. 196: 69, 1982.
74. Calabro, A., Singletary, S. E., and Balch, C. M. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch. Surg. 124: 1051, 1989.
75. Bevilaqua, R. G., Coit, D. G., Rogatko, A., Younes, R. N., and Brennan, M. F. Axillary dissection in melanoma: Prognostic variables in node-positive patients. Ann. Surg. 212: 125, 1990.
76. Karakousis, C. P., Stahl, L., Moore, R., and Holyoke, E. D. Lymph node dissection in malignant melanoma. J. Surg. Oncol. 13: 245, 1980.
77. Reintgen, D. S., Cox, E. B., McCarty, K. S., Jr., Vollmer, R. T., and Seigler, H. F. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann. Surg. 198: 379, 1983.
78. Milton, G. W., Shaw, H. M., McCarthy, W. H., Pearson, L., Balch, C. M., and Soong, S. J. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: Results of surgical treatment in 1,319 patients. Br. J. Surg. 69: 108, 1982.
79. Balch, C. M., Soong, S. J., Milton, G. W., et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, U.S.A., and New South Wales, Australia. Ann. Surg. 196: 677, 1982.
80. Morton, D. L., Wanek, L., Nizze, J. A., Elashoff, R. M., and Wong, J. H. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: An analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann. Surg. 214: 491, 1991.
81. McCarthy, W. H., Shaw, H. M., and Milton, G. W. Efficacy of elective lymph node dissection in 2,347 patients with clinical stage I malignant melanoma. Surg. Gynecol. Obstet. 161: 575, 1985.
82. Drepper, H., Kohler, C. O., Bastian, B., et al. Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patients. Cancer 72: 741, 1993.
83. Veronesi, U., Adamus, J., Bandiera, D. C., et al. Stage I melanoma of the limbs. Immediate versus delayed lymph node dissection. Tumori 66: 373, 1980.
84. Sim, F. H., Taylor, W. F., Pritchard, D. J., and Soule, E. H. Lymphadenectomy in the management of stage I malignant melanoma: A prospective randomized study. Mayo Clin. Proc. 61: 697, 1986.
85. Cascinelli, N., Morabito, A., Santinami, M., MacKie, R. M., and Belli, F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial. WHO Melanoma Programme. Lancet 351: 793, 1998.
86. Balch, C. M., Soong, S. J., Bartolucci, A. A., et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann. Surg. 224: 255, 1996.
87. Buzaid, A. C., Tinoco, L. A., Jendiroba, D., et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J. Clin. Oncol. 13: 2361, 1995.
88. Karakousis, C. P., Seddiq, M. K., and Moore, R. Prognostic value of lymph node dissection for malignant melanoma. Ann. Surg. 115: 719, 1980.
89. Day, C. L., Jr., Sober, A. J., Lew, R. A., et al. Malignant melanoma patients with positive nodes and a relatively good prognoses: Microstaging retains prognostic significance in clinical stage I patients with meastases to regional nodes. Cancer 47: 955, 1981.
90. Cascinelli, N., Vaglini, M., Nava, M., et al. Prognosis of skin melanoma with regional node metastases (stage II). J. Surg. Oncol. 25: 240, 1984.
91. Balch, C. M., Soong, S. J., Murad, T. M., Ingalls, A. L., and Maddox, W. A. A multifactorial analysis of melanoma III: Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann. Surg. 193: 377, 1981.
92. Morton, D. L., Wen, D. R., Wong, J. H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 127: 392, 1992.
93. Norman, J., Cruse, C. W., Espinosa, C., et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am. J. Surg. 162: 432, 1991.
94. Reintgen, D., Cruse, C. W., Wells, K., et al. The orderly progression of melanoma nodal metastases. Ann. Surg. 220: 759, 1994.
95. Krag, D. L., Meijer, S. J., Weaver, D. L., et al. Minimal-access surgery for staging of malignant melanoma. Arch. Surg. 130: 654, 1995.
96. Albertini, J. J., Cruse, C. W., Rapaport, D., et al. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann. Surg. 223: 217, 1996.
97. Pijpers, R., Collet, G. J., Meijer, S., and Hoekstra, O. S. The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma. Eur. J. Nucl. Med. 22: 1238, 1995.
98. Van der Veen, H., Hoekstra, O. S., Paul, M. A., Cuesta, M. A., and Meijer, S. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br. J. Surg. 81: 1769, 1994.
99. Uren, R. F., Howman-Giles, R. B., Shaw, H. M., Thompson, J. F., and McCarthy, W. H. Lymphoscintigraphy in high-risk melanoma of the trunk: Predicting draining node groups, defining lymphatic channels, and locating the sentinel node. J. Nucl. Med. 34:1435, 1993.
100. Mudun, A., Murray, D. R., Herda, S. C., et al. Early stage melanoma: Lymphoscintigraphy, reproducibility of sentinel node detection, and effectiveness of the intraoperative gamma probe. Radiology 199: 171, 1996.
101. Morton, D. L., and Bostick, P. J. Will the true sentinel node please stand? Ann. Surg. Oncol. 6: 12, 1999.
102. Nathanson, D. S., Nelson, L., and Karvelis, K. C. Rates of flow of technetium-99m-labeled human serum albumin from peripheral injection sites to sentinel lymph nodes. Ann. Surg. Oncol. 3: 329, 1996.
103. Glass, E. C., Essner, R., and Morton, D. L. Kinetics of three lymphoscintigraphic agents in patients with cutaneous melanoma. J. Nucl. Med. 39: 1185, 1998.
104. Wong, J. H., Terada, K., Ko, P., and Coel, M. N. Lack of effect of particle size on the identification of the sentinel node in cutaneous malignancies. Ann. Surg. Oncol. 5: 77, 1998.
105. Goldfarb, L. R., Alazraki, N. P., Eshima, D., Eshima, L. A., Herda, S. C., and Halkar, R. K. Lymphoscintigraphic identification of sentinel lymph nodes: Clinical evaluation of 0.22 micron filtration of tc-99m sulfur colloid. Radiology 208: 505, 1998.
106. Tafra, L., Chua, A. N., Ng, P. C., Aycock, D., Swanson, M., and Lannin, D. Filtered versus unfiltered technetium sulfur colloid in lymphatic mapping: A significant variable in a pig model. Ann. Surg. Oncol. 6: 83, 1999.
107. Morton, D. L., Giuliano, A. E., Reintgen, D. S., Roses, D. F., Ross, M. I., and Thompson, J. F. Symposium: Lymphatic mapping and sentinel node biopsy in patients with breast cancer and melanoma - Part 1. Contemp. Surg. 53: 281, 1998.
108. Morton, D. L., Giuliano, A. E., Reintgen, D. S., Roses, D. F., Ross, M. I., and Thompson, J. F. Symposium: Lymphatic mapping and sentinel node biopsy in patients with breast cancer and melanoma - Part 2. Contemp. Surg. 53: 353, 1998.
109. O'Brien, C. J., Uren, R. F., Thompson, J. F., et al. Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. Am. J. Surg., 170: 461, 1995.
110. Wagner, J. D., Davidson, D., Coleman, J. J., III, et al. Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma. Ann. Surg. Oncol. 6: 398, 1999.
111. Gershenwald, J. E., Colome, M. I., Lee, J. E., et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J. Clin. Oncol. 16: 2253, 1998.
112. Cochran, A. J., Wen, D. R., and Morton, D. L. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study. Am. J. Surg. Pathol. 12: 612, 1988.
113. Shivers, S. C., Wang, X., and Li, W., et al. Molecular staging of malignant melanoma: Correlation with clinical outcome. J.A.M.A. 280: 1410, 1998.
114. Morton, D. L., Wen, D. R., Foshag, L. J., Essner, R., and Cochran, A. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J. Clin. Oncol. 11: 1751, 1993.
115. Wagner, J. D., Corbett, L., Park, H. M., et al. Sentinel lymph node biopsy for cutaneous melanoma: Experience with 234 consecutive procedures. Plast. Reconstr. Surg. (in press).
116. Gershenwald, J. E., Thompson, W., Mansfield, P. F., et al. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J. Clin. Oncol. 17: 976, 1999.
117. Mraz-Gernhard, S., Sagebiel, R. W., Kashani-Sabet, M., Miller, J. R., III, and Leong, S. P. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch. Dermatol. 134: 983, 1998.
118. Joseph, E., Brobeil, A., Glass, F., et al. Results of complete lymph node dissection in 83 patients with positive sentinel nodes. Ann. Surg. Oncol. 5: 119, 1998.
119. Haddad, F. F., Stall, A., Messina, J., et al. The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion. Ann. Surg. Oncol. 6: 144, 1999.
120. Borgstein, P., Pijpers, R., van Diest, P., and Meijer, S. Staging early lymphatic metastases in melanoma: The case for super-selective lymph node dissection (Abstract). Prog. Proc. Soc. Surg. Oncol. 51: 63, 1998.
121. Haigh, P. R., Bostick, P., Turner, R., Cochran, A., Essner, R., and Morton, D. L. The role of age and pathologic pattern of regional metastasis in sentinel lymph node dissection for melanoma (Abstract). Proc. Am. Soc. Clin. Oncol. 17: 506, 1998.
122. MacKie, R. M., Byrne, D., Lyngam, M. K., Sajid, M., and MacKay, A. K. Prognostic evaluation of sentinel node biopsy (Abstract). Melanoma Res. 7: S102, 1997.
123. Sondak, V. K., and Wolfe, J. A. Adjuvant therapy of melanoma. Curr. Opin. Oncol. 9: 189, 1997.
124. Nathanson, L. Interferon adjuvant therapy of melanoma. Cancer 78: 944, 1996.
125. Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., and Blum, R. H. Interferon-α-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial Est 1684. J. Clin. Oncol. 14: 7, 1996.
126. Kirkwood, J. M., Ibrahim, J., Sondak, V., et al. Preliminary analysis of the E1690/C9190 intergroup post-operative adjuvant trial of high and low dose interferon-2b (HDI and IDI) in high risk primary or lymph node metastatic melanoma (Abstract). Proc. Am. Soc. Clin. Oncol. 18: 537, 1999.
127. Balch, C. M., and Buzaid, A. C. Finally, a successful adjuvant therapy for high risk melanoma. J. Clin. Oncol. 14: 1, 1996.
128. Coit, D. G. Patient Surveillance and Follow-Up. In C. M. Balch, A. N. Houghton, A. J. Sober, and S. J. Soong (Eds.), Cutaneous Melanoma, 3rd Ed. St. Louis: Quality Medical Publishing, 1998. Pp. 313-323.
129. McCarthy, W. H., Shaw, H. M., Thompson, J. F, and Milton, G. W. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg. Gynecol. Obstet. 166: 497, 1988.
130. Tsao, H., Cosimi, A. B., and Sober, A. J. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 79: 2361, 1997.
131. Karakousis, C. P., Emrich, L. J., and Rao, U. Groin dissection in malignant melanoma. Am. J. Surg. 152: 491, 1986.
132. Jonk, A., Kroon, B. B., Rumke, P., Van der Esch, E. P., and Hart, A. A. Results of radical dissection of the groin in patients with stage II melanoma and histologically proved metastases of the iliac or obturator lymph nodes, or both. Surg. Gynecol. Obstet. 167:28 1988.
133. Monsour, P. D., Sause, W. T., Avent, J. M., and Noyes, R. D. Local control following therapeutic nodal dissection for melanoma. J. Surg. Oncol. 54: 18, 1993.
134. Byers, R. M. The role of modified neck dissection in the treatment of cutaneous melanoma of the head and neck. Arch. Surg. 121: 1338, 1986.
135. Singletary, S. E., Byers, R. M., Shallenberger, M. P. H., McBride, C. M., and Guinee, V. F. Prognostic factors in patients with regional cervical nodal metastases from cutaneous malignant melanoma. Am. J. Surg. 152: 371, 1986.
136. Ang, K. K., Peters, L. J., Weber, R. S., et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int. J. Radiat. Oncol. Biol. Phys. 30: 795, 1994.
137. Creagan, E. T., Cupps, R. E., Ivins, J. C., et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: A randomized, prospective study. Cancer 42: 2206, 1978.
138. Karakousis, C. P., Bartolucci, A. A., and Balch, C. M. Local Recurrence and its Management. In C. M. Balch, A. N. Houghton, A. J. Sober, and S. J. Soong (Eds.), Cutaneous Melanoma, 3rd Ed. St. Louis: Quality Medical Publishing, 1998. Pp. 155-162.
139. Leon, P., Daly, J. M., Synnestvedt, M., Schultz, D. J., Elder, D. E., and Clark, W. H., Jr. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch. Surg. 126: 1461, 1991.
140. Karakousis, C. P., Balch, C. M., Urist, M. M., Ross, M. M., Smith, T. J., and Bartolucci, A. A. Local recurrence in malignant melanoma: Long-term results of the multiinstitutional randomized surgical trial. Ann. Surg. Oncol. 3: 446, 1996.
141. Brown, C. D., and Zitelli, J. A. The prognosis and treatment of true local cutaneous recurrent malignant melanoma. Dermatol. Surg. 21: 285, 1995.
142. Fraker, D. L. Hyperthermic Regional Perfusion for Melanoma of the Limbs. In C. M. Balch, A. N. Houghton, A. J. Sober, and S. J. Soong (Eds.), Cutaneous Melanoma, 3rd Ed. St. Louis: Quality Medical Publishing, 1998. Pp. 281-300.
143. Koops, H. S., Vaglini, M., Suciu, S., et al. Prophylactic isolated limb perfusion for localized high-risk limb melanoma: Results of a multicenter randomized phase III trial. J. Clin. Oncol. 16: 2906, 1998.
144. Coit, D. G. Recurrent Regional Metastases and Their Management. In C. M. Balch, A. N. Houghton, A. J. Sober, and S. J. Soong (Eds.), Cutaneous Melanoma, 3rd Ed. St. Louis: Quality Medical Publishing 1998. Pp. 301-309.
145. Fraker, D. L., Alexander, H. R., Bartlett, D., et al. A prospective randomized trial of therapeutic isolated limb perfusion (ILP) comparing melphalan (M), tumor necrosis factor (TNF) and interferon gamma (INFγ): An initial report (Abstract). Prog. Proc. Soc Surg. Oncol. 29: 6, 1996.
146. Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N., and Lejeune, F. J. High-dose recombinant tumor necrosis factor alpha in combination with interferon-gamma and melphalan in isolation perfusion of limbs for melanoma and sarcoma. J. Clin. Oncol. 10:52, 1992.
147. Anderson, C. M., Buzaid, A. C., and Legha, S. S. Systemic treatments for advanced cutaneous melanoma Oncology 9: 1149, 1995.
148. Myers, M. L., and Balch, C. M. Diagnosis and Treatment of Metastatic Melanoma. In C. M. Balch, A. N. Hough ton, A. J. Sober, and S. J. Soong (Eds.), Cutaneous Melanoma, 3rd Ed. St. Louis: Quality Medical Publishing, 1998. Pp. 325-372.
149. Berger, A. C., Buell, J. F., Venzon, D., Baker, A. R., and Libutti, S. K. Management of symptomatic malignant melanoma of the gastrointestinal tract. Ann. Surg. Oncol. 6: 155, 1999.
150. Buzaid, A. C., Bedikian, A., and Houghton, A. N. Systemic Chemotherapy and Biochemotherapy. In C. M. Balch, A. N. Houghton, A. J. Sober, and S. J. Soong (Eds.), Cutaneous Melanoma, 3rd Ed. St. Louis: Quality Medical Publishing, 1998. Pp. 405-418.
151. Saxman, S. B., Meyers, M. L., Chapman, P. B., et al. A phase III multicenter randomized trial of DTIC, cisplatin, BCNU and tamoxifen versus DTIC alone in patients with metastatic melanoma (Abstract). Proc. Am. Soc. Clin. Oncol. 18: 536, 1999.
152. Rosenberg, S. A., Yang, J. C., Topalian, S. L., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. J.A.M.A. 271:907, 1994.
153. Ang, K. K., Geara, F. B., Byers, R. M., and Peters, L. J. Radiotherapy for Melanoma. In C. M. Balch, A. N. Houghton, A. J. Sober, and S. J. Soong (Eds.), Cutaneous Melanoma, 3rd Ed. St. Louis: Quality Medical Publishing, 1998. Pp. 389-403.
154. Somaza, S., Kondziolka, D., Lunsford, L. D., Kirkwood, J. M., and Flickinger, J. C. Stereotactic radiosurgery for cerebral metastatic melanoma. J. Neurosurg. 79: 661, 1993.
155. Legha, S. S., Ring, S., Eton, O., et al. Development of biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon-α and interleukin-2 or patients with metastatic melanoma. J. Clin. Oncol. 16: 1752, 1998.
156. Keilholz, U., Conradt, C., Legha, S. S., et al. Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients J. Clin. Oncol. 16: 2921, 1998.
157. Morton, D. L., and Barth, A. Vaccine therapy for malignant melanoma. CA Cancer J. Clin. 46: 224, 1996.
158. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321, 1998.
159. Brobeil, A., Rapaport, D., Wells, K., et al. Multiple primary melanomas: Implications for screening and follow-up programs for melanoma. Ann. Surg. Oncol. 4: 19, 1997.